Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature

scientific article published on 13 August 2014

Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/BJU.12771
P932PMC publication ID4352319
P698PubMed publication ID24731026
P5875ResearchGate publication ID263310561

P50authorMark W. BallQ41496168
Ashley E. RossQ57023811
Edward M SchaefferQ62069731
Alan W PartinQ62089936
Misop HanQ63022456
Debasish SundiQ63253312
Jonathan I. EpsteinQ88404078
H Ballentine CarterQ114718059
P2093author name stringTrinity J Bivalacqua
Phillip M Pierorazio
Farzana A Faisal
Elizabeth B Humphreys
P2860cites workPathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American menQ33702311
Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancerQ35605945
'Prostatic evasive anterior tumours': the role of magnetic resonance imagingQ37611898
Active surveillance for clinically localized prostate cancer--a systematic reviewQ38194533
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapyQ39797017
High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsyQ40101873
Predictors of Gleason score upgrading in a large African-American populationQ40125227
Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimensQ41727000
Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6.Q41863428
The clinical features of anterior prostate cancersQ43034645
Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysisQ43766423
Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumoursQ44623612
Pretreatment predictors of time to cancer specific death after prostate specific antigen failureQ44952969
Active surveillance program for prostate cancer: an update of the Johns Hopkins experienceQ45133435
Biological determinants of cancer progression in men with prostate cancer.Q51090543
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.Q55067996
Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomyQ59649550
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancerQ71606146
Correlation of pathologic findings with progression after radical retropubic prostatectomyQ72079964
Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapyQ73203851
Calculated volume of prostate cancer identifies patients with clinical stage T1C disease at high risk of biochemical recurrence after radical prostatectomy: a preliminary studyQ74107626
Contemporary evaluation of the D'amico risk classification of prostate cancerQ80168461
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factorsQ80388277
P433issue6b
P304page(s)E120-E129
P577publication date2014-08-13
P1433published inBJU InternationalQ4835773
P1476titleOutcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature
P478volume114